Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

The coagulopathy and thrombotic risk associated with L-Asparaginase treatment in adults with acute lymphoblastic leukaemia

Leukemia volume 27, pages 553–559 (2013)Cite this article

Subjects

Abstract

The dramatic improvements seen in the outcome of paediatric patients with acute lymphoblastic leukaemia (ALL) have led to increasing incorporation of L-asparaginase (L-Asp) in adult treatment protocols. However, its use is associated with a disruption in the physiological balance between haemostatic and anticoagulant pathways, with the predominant clinical manifestation being thrombosis. Although L-Asp therapy is known to be associated with an acquired deficiency of antithrombin (AT), the concurrent depletion of fibrinogen and other haemostatic proteins means that the precise mechanism of thrombosis remains to be defined. In vitro coagulation assays are often prolonged but thrombosis rather than haemorrhage is the primary concern. Management of thrombotic events in these patients is based around agents that rely on AT for their anticoagulant effect, even though it is usually depleted. There is currently only limited evidence supporting the use of AT concentrates in either primary prevention or management following an established event. Evidence-based guidelines for prevention and management strategies are lacking.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Kidd JG . Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. J Exp Med 1953; 98: 565–582.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Broome JD . Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. J Exp Med 1963; 118: 99–120.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ertel IJ, Nesbit ME, Hammond D, Weiner J, Sather H . Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphoblastic leukemia: a report from children’s cancer study group. Cancer Res 1979; 39: 3893–3896.

    CAS  PubMed  Google Scholar 

  4. Douer D . Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia? Best Pract Res Clin Haematol 2008; 21: 647–658.

    Article  CAS  PubMed  Google Scholar 

  5. Pui CH, Evans WE . Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166–178.

    Article  CAS  PubMed  Google Scholar 

  6. Seibel NL . Treatment of acute lymphoblastic leukemia in children and adolescents: peaks and pitfalls. Hematology Am Soc Hematol Educ Program 2008; 1: 374–380.

    Article  Google Scholar 

  7. Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei E, Nathan DG . Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983; 43: 5601–5607.

    CAS  PubMed  Google Scholar 

  8. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97: 1211–1218.

    Article  CAS  PubMed  Google Scholar 

  9. Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A et al. L-asparaginase treatment in acute lymphoblastic leukemia. A focus on Erwinia asparaginase. Cancer 2011; 117: 238–249.

    Article  CAS  PubMed  Google Scholar 

  10. Payne JH, Vora AJ . Thrombosis and acute lymphoblastic leukaemia. Br J Haematol 2007; 138: 430–445.

    Article  PubMed  Google Scholar 

  11. Grace RF, Dahlberg SE, Neuberg D, Sallan SE, Connors JM, Neufeld EJ et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol 2011; 152: 452–459.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Mitchell LG, Andrew M, Hanna K, Abshire T, Halton J, Anderson R et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase. Results of the prophylactic antithrombin replacement in kids treated with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer 2003; 97: 508–516.

    Article  CAS  PubMed  Google Scholar 

  13. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Mariani G, de Gaetano G et al. Thrombotic complications in childhood acute lymphoblastic: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006; 108: 2216–2222.

    Article  CAS  PubMed  Google Scholar 

  14. Elliot MA, Wolf RC, Hook CC, Pruthi RK, Heit JA, Letendre LL et al. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin. Leuk Lymphoma 2004; 45: 1545–1549.

    Article  Google Scholar 

  15. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Donati MB . Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis. J Thromb Haemost 2007; 5: 621–623.

    Article  CAS  PubMed  Google Scholar 

  16. Kantarjian HM, O’Brien S, Smith TL, Cortes J, Giles FJ, Beran M et al. Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547–561.

    Article  CAS  PubMed  Google Scholar 

  17. Gugliotta L, Mazzucconi MG, Leone G, Mattioli-Belmonte M, Defazio D, Annino L et al. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA group. Eur J Haematol 1992; 49: 63–66.

    Article  CAS  PubMed  Google Scholar 

  18. Abbott LS, Deevska M, Fernandez CV, Dix D, Price VE, Wang H et al. The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and haemorrhage in children with acute lymphoblastic leukemia receiving asparaginase. Blood 2009; 114: 5146–5151.

    Article  CAS  PubMed  Google Scholar 

  19. Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European organisation for research and treatment of cancer – children’s leukemia group phase 3 trial. Blood 2002; 99: 2734–2739.

    Article  CAS  PubMed  Google Scholar 

  20. Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C et al. Results of the Dana-Farber Cancer Institute ALL consortium protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109: 896–904.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Carlsson H, Stockelberg D, Tengborn L, Braide I, Carneskog J, Kutti J . Effects of Erwinia-asparaginase on the coagulation system. Eur J Haematol 1995; 55: 289–293.

    Article  CAS  PubMed  Google Scholar 

  22. Risseeuw-Appel IM, Dekker I, Hop WC, Hahlen K . Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: a randomized study. Med Pediatr Oncol 1994; 23: 335–343.

    Article  CAS  PubMed  Google Scholar 

  23. Avramis VI, Spencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood 2002; 99: 1986–1994.

    Article  CAS  PubMed  Google Scholar 

  24. Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood 2010; 115: 1351–1353.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MT, Fliers E et al. Hypercoagulable state in Cushing’s syndrome: a systemic review. J Clin Endocrinol Metab 2009; 94: 2743–2750.

    Article  CAS  PubMed  Google Scholar 

  26. Van Zaane B, Nur E, Squizzato A, Gerdes VE, Buller HR, Dekkers OM et al. Systemic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors. J Thromb Heamost 2010; 8: 2483–2493.

    Article  CAS  Google Scholar 

  27. Isacson S . Effect of prednisolone on the coagulation and fibrinolytic systems. Scand J Haematol 1970; 7: 212–216.

    Article  CAS  PubMed  Google Scholar 

  28. Ozsoylu S, Strauss HS, Diamond LK . Effects of corticosteroids on coagulation of blood. Nature 1962; 195: 1214–1215.

    Article  CAS  PubMed  Google Scholar 

  29. Brotman DJ, Girod JP, Posch A, Jani JT, Patel JV, Gupta M et al. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res 2006; 118: 247–252.

    Article  CAS  PubMed  Google Scholar 

  30. Esmon CT . Inflammation and thrombosis. J Thromb Haemost 2003; 1: 1343–1348.

    Article  CAS  PubMed  Google Scholar 

  31. Nowak-Gottl U, Ahlke E, Fleischhack G, Schwabe D, Schobess R, Schumann C et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood 2003; 101: 2529–2533.

    Article  CAS  PubMed  Google Scholar 

  32. Van Den Berg H . Asparaginase revisited. Leuk Lymphoma 2011; 52: 168–178.

    Article  CAS  PubMed  Google Scholar 

  33. Earl M . Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. Clin Adv Haematol Oncol 2009; 7: 600–606.

    Google Scholar 

  34. Asselin BL, Ryan D, Frantz CN, Bernal SD, Leavitt P, Sallan SE et al. In vitro killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res 1989; 49: 4363–4368.

    CAS  PubMed  Google Scholar 

  35. Rytting M . PEG-asparaginase for acute lymphoblastic leukemia. Expert Opin Biol Ther 2010; 10: 833–839.

    Article  CAS  PubMed  Google Scholar 

  36. Ueno T, Ohtawa K, Mitsui K, Kodera Y, Hiroto M, Matsushima A et al. Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase. Leukemia 1997; 11: 1858–1861.

    Article  CAS  PubMed  Google Scholar 

  37. Grigoryan RS, Panosyan EH, Seibel NL, Gaynon PS, Avramis IA, Avramis VI . Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961). In Vivo 2004; 18: 107–112.

    CAS  PubMed  Google Scholar 

  38. Cory JG, Cory AH . Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: asparaginase treatment in childhood acute lymphoblastic leukemia. In Vivo 2006; 20: 587–590.

    CAS  PubMed  Google Scholar 

  39. Zakarija A, Kwaan HC . Adverse effects on hemostatic function of drugs used in hematologic malignancies. Semin Thromb Hemost 2007; 33: 355–364.

    Article  CAS  PubMed  Google Scholar 

  40. Ramsey NK, Coccia PF, Krivit W, Nesbit ME, Edson JR . The effect of L-asparaginase of plasma coagulation factors in acute lymphoblastic leukemia. Cancer 1977; 40: 1398–1401.

    Article  Google Scholar 

  41. Pui CH, Jackson CW, Chesney C, Lyles SA, Bowman WP, Abromowitch M et al. Sequential changes in platelet function and coagulation in leukemic children treated with L-asparaginase, prednisolone and vincristine. J Clin Oncol 1983; 1: 380–385.

    Article  CAS  PubMed  Google Scholar 

  42. Homans AC, Rybak ME, Baglini RL, Tiarks C, Steiner ME, Forman EN . Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia. J Clin Oncol 1987; 5: 811–817.

    Article  CAS  PubMed  Google Scholar 

  43. Furie B, Furie BC . Mechanisms of thrombus formation. N Engl J Med 2008; 359: 938–949.

    Article  CAS  PubMed  Google Scholar 

  44. Leihanacova-Tousovska K, Zapletal O, Vytiskova S, Strbackova P, Sterba J . Profile of thrombin generation in children with acute lymphoblastic leukaemia treated by Berlin-Frankfurt-Munster (BFM) protocols. Blood Coagul Fibribolysis 2012; 23: 144–145.

    Article  Google Scholar 

  45. Patnaik MM, Moll S . Inherited antithrombin deficiency: a review. Haemophilia 2008; 14: 1229–1239.

    Article  CAS  PubMed  Google Scholar 

  46. Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M . Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L-asparaginase-induced antithrombin deficiency. Blood 1994; 83: 386–391.

    CAS  PubMed  Google Scholar 

  47. Hunault-Berger M, Chevallier Delain M, Bulabois CE, Bologna S, Bernard M et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica 2008; 93: 1488–1494.

    Article  CAS  PubMed  Google Scholar 

  48. Hernandez-Espinosa D, Ordonez A, Vicente V, Corral J . Factors with conformational effects on haemostatic serpins: implications for thrombosis. Thromb Haemost 2007; 98: 557–563.

    Article  CAS  PubMed  Google Scholar 

  49. Bushman JE, Palmieri D, Whinna HC, Church FC . Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia. Leuk Res 2000; 24: 559–565.

    Article  CAS  PubMed  Google Scholar 

  50. Hernandez-Espinosa D, Minano A, Martinez C, Perez-Ceballos E, Heras I et al. L-asparaginase-induced antithrombin type 1 deficiency. Implications for conformational diseases. Am J Pathol 2006; 169: 142–153.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Nowak-Gottl U, Boos J, Wolff JE, Lill H, Veltmann H, Werber G et al. Asparaginase decreases clotting factors in vitro: a possible pitfall? Int J Clin Lab Res 1995; 25: 146–148.

    Article  CAS  PubMed  Google Scholar 

  52. Walker ID, Greaves M, Preston FE . Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114: 512–528.

    Article  CAS  Google Scholar 

  53. Vigano-D’Angelo S, Gugliotta L, Mattioli Belmonte M, Cascione ML, Pattarini E, D’Angelo A . L-asparaginase treatment reduces the anticoagulant potential of the protein C system without affecting vitamin K-dependent carboxylation. Thromb Res 1990; 59: 985–994.

    Article  Google Scholar 

  54. Gugliotta L, D’Angelo A, Mattioli Belmonte M, Vigano-D’Angelo S, Colombo G, Catani L et al. Hypercoagulability during L-asparaginase treatment: the effect of antithrombin III supplementation in vivo. Br J Haematol 1990; 74: 465–470.

    Article  CAS  PubMed  Google Scholar 

  55. Nowak-Gottl U, Werber G, Ziemann D, Ahlke E, Boos J . Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL. Haematologica 1996; 81: 127–131.

    CAS  PubMed  Google Scholar 

  56. Jaime-Perez JC, Gomez-Almaguer D . Platelet aggregation is stimulated by L-asparaginase in children with acute lymphoblastic leukemia and in normal individuals. Haematologica 2002; 87: 891–892.

    PubMed  Google Scholar 

  57. Hunt BJ, Jurd KM . Endothelial cell activation - a central pathophysiological process. BMJ 1998; 316: 1328.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Gresele P, Momi S, Migliacci R . Endothelium, venous thromboembolism and ischaemic cardiovascular events. Thromb Haemost 2010; 103: 56–61.

    Article  CAS  PubMed  Google Scholar 

  59. Giordano P, Molinari AC, Del Vecchio GC, Saracco P, Russo G, Altomare M et al. Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia. Am J Haematol 2010; 85: 325–330.

    CAS  Google Scholar 

  60. Schneider P, Van Dreden P, Rousseau A, Kassim Y, Legrand E, Vannier JP et al. Increased levels of tissue factor activity and procoagulant phospholipids during treatment of children with acute lymphoblastic leukemia. Br J Haematol 2009; 148: 582–592.

    Article  PubMed  Google Scholar 

  61. McLean TW, Fisher CJ, Snively BM, Chauvenet AR . Central venous lines in children with lesser risk acute lymphoblastic leukemia: optimal type and timing of placement. J Clin Oncol 2005; 23: 3024–3029.

    Article  PubMed  Google Scholar 

  62. Nowak-Gottl U, Kuhn N, Wolff JE, Boos J, Kehrel B, Rath B et al. Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children. Eur J Haematol 1996; 56: 35–38.

    Article  CAS  PubMed  Google Scholar 

  63. Gollop ND, Chilcott J, Benton A, Rayment R, Jones J, Collins PW . National audit of the use of fibrinogen concentrate to correct hypofibrinogenaemia. Transfus Med 2012; 22: 350–355.

    Article  CAS  PubMed  Google Scholar 

  64. Mitchell L, Andrew M, Hanna K, Abshire T, Halton J, Wu J et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving L-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003; 90: 163–164.

    Article  Google Scholar 

  65. CG92 Venous thromboembolism – reducing the risk: NICE guideline 2010.

  66. Elhasid R, Lanir N, Sharon R, Weyl Ben Arush M, Levin C, Postovsky S et al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibribolysis 2001; 12: 367–370.

    Article  CAS  Google Scholar 

  67. Qureshi A, Mitchell C, Richards S, Vora A, Goulden N . Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe. Br J Haematol 2010; 149: 410–413.

    Article  CAS  PubMed  Google Scholar 

  68. Kuhle S, Lau A, Bajzar L, Vegh P, Halton J, Cherrick I et al. Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study. Br J Haematol 2006; 134: 526–531.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Centre for Clinical Haematology, Nottingham University Hospitals, Nottingham, UK

    E Truelove

  2. Department of Haematology, University College London, London, UK

    A K Fielding

  3. Departments of Haematology, Pathology and Rheumatology, Kings College London, London, UK

    B J Hunt

Authors
  1. E Truelove
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A K Fielding
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B J Hunt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E Truelove.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Truelove, E., Fielding, A. & Hunt, B. The coagulopathy and thrombotic risk associated with L-Asparaginase treatment in adults with acute lymphoblastic leukaemia. Leukemia 27, 553–559 (2013). https://doi.org/10.1038/leu.2012.290

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2012.290

Keywords

This article is cited by

Search

Advanced search

Quick links